<DOC>
	<DOCNO>NCT00039299</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop tumor cell grow . Treating person 's T cell laboratory reinfusing may cause strong immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness T-cell therapy treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety activate autologous T cell ( Xcellerate ) therapy patient hormone-refractory prostate cancer . - Determine change prostate-specific antigen ( PSA ) level patient treat therapy . - Determine effect bone patient treated therapy . OUTLINE : This multicenter study . Patients undergo leukapheresis collect peripheral blood mononuclear cell ( PBMC ) . PBMC activate expand ex vivo costimulation antihuman CD3 antihuman CD28 monoclonal antibody covalently attach superparamagnetic microbeads ( Xcellerate ) . Xcellerate-activated T cell reinfused day 0 . Patients follow weekly 4 week monthly 3 month . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Evidence androgenindependent disease Patient must receive prior primary hormonal therapy ( e.g. , orchiectomy gonadotropinreleasing hormone analog without antiandrogen ) Demonstrated disease progression 1 following : Elevated PSA level ( least 5 ng/mL ) serially rise baseline 2 occasion least 1 week apart At least 1 new osseous lesion bone scan More 25 % increase sum product perpendicular diameter bidimensionally measurable site disease No CNS metastases PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGPT great 1.5 time ULN Hepatitis B surface antigen negative No active chronic hepatitis B C No hepatic dysfunction would preclude study Renal : Creatinine le 2.0 mg/dL Calcium le 11 mg/dL No renal dysfunction would preclude study No symptomatic hypercalcemia Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No pulmonary disease require inhaled steroid bronchodilator Other : No history HIV 1 2 human Tcell lymphotrophic virus ( HTLV ) 1 2 No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer No history autoimmune disease ( e.g. , rheumatoid arthritis multiple sclerosis ) No major organ system dysfunction No gastrointestinal , neurologic , psychiatric dysfunction would preclude study Human antimouse antibody negative PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent growth factor , interleukin , interferon , cytokine Chemotherapy : No prior chemotherapy systemic chemotherapy agent prostate cancer Endocrine therapy : Prior aminoglutethimide allow At least 4 week since prior flutamide At least 6 week since prior bicalutamide nilutamide Concurrent luteinizing hormonereleasing hormone agonist continue No concurrent corticosteroids dexamethasone No concurrent antiandrogens ( e.g. , flutamide , bicalutamide , nilutamide ) Radiotherapy : At least 4 week since prior local radiotherapy No prior radiopharmaceutical therapy ( e.g. , strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium ) No concurrent radiotherapy Surgery : Not specify Other : Prior ketoconazole PCSPES allow At least 1 week since prior antibiotic , antifungal , antiviral agent At least 4 week since prior systemic therapy prostate cancer ( except bisphosphonates hormonal therapy ) At least 6 week since prior investigational drug device No concurrent therapy disease No concurrent participation another clinical trial No concurrent bisphosphonates unless initiate prior study No concurrent immunosuppressive drug No concurrent experimental therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>